Victoria M. Richon - Concepedia

Author

Victoria M. Richon

Also Known As

V M Richon, V Richon, V. M. Richon, V. Richon, VICTORIA M. RICHON, VICTORIA RICHON, Victoria M Richon, Victoria M. Richon, Victoria Richon, Victoria M. Richon

216

Publications

31.2K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Merck & Co., Inc., Rahway, NJ, USA (United States)Epizyme (United States)Cornell University Dana-Farber Cancer Institute

About

Victoria M. Richon is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, cell biology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	40	51	12.4K
2	Natural Sciences	15	15	4.5K
3	Biochemistry	11	11	2.9K
4	Engineering	1	1	757
5	Health Sciences	1	1	99

Victoria M. Richon

Publications

25.8K

Citations

H-Index

Page 1

	Year	Citations
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors Michael S. Finnin, Jill R. Donigian, Alona Cohen, Nature Histone ModificationsChromatinChromatin StructureBiochemistryChromatin Remodeling	1999	1.7K
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Madeleine Duvic, Rakshandra Talpur, Xiao Ni, Blood	2006	1.1K
Histone deacetylase inhibitor selectively induces p21 <sup>WAF1</sup> expression and gene-associated histone acetylation Victoria M. Richon, Todd W. Sandhoff, Richard A. Rifkind, Proceedings of the National Academy of Sciences	2000	1.1K
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor Scott R. Daigle, Edward J. Olhava, Carly A. Therkelsen, Cancer Cell Hematological MalignancyTumor BiologySelective KillingMedicineMixed-phenotype Acute Leukemia	2011	923
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases Victoria M. Richon, Stéphane Emiliani, Eric Verdin, Proceedings of the National Academy of Sciences	1998	911
Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer William Kevin Kelly, Owen A. O’Connor, Lee M. Krug, Journal of Clinical Oncology	2005	898
MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L Kathrin M. Bernt, Nan Zhu, Amit Sinha, Cancer Cell Hematological MalignancyTumor BiologyChromatinEpigenetic ChangeCancer Cell Biology	2011	883
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease Emma Hockly, Victoria M. Richon, Benjamin Woodman, Proceedings of the National Academy of Sciences	2003	836
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 Sarah K. Knutson, Natalie M. Warholic, Tim J. Wigle, Proceedings of the National Academy of Sciences EngineeringChemoprevention StrategySmarcb1-deleted Mrt CellsPathologyCancer Biology	2013	757
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells Sarah K. Knutson, Tim J. Wigle, Natalie M. Warholic, Nature Chemical Biology Lymphoid NeoplasiaMedicineSelective InhibitorAnti-cancer AgentTumor Suppressor	2012	753

Page 1